[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Miller DS, King LP: Gynecologic oncology group trials in uterine corpus malignancies: recent progress. J Gynecol Oncol; 2008 Dec;19(4):218-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecologic oncology group trials in uterine corpus malignancies: recent progress.
  • The Gynecologic Oncology Group (GOG) has conducted multiple trials related to malignancies of the uterine corpus.
  • Areas of focus included the feasibility of laparoscopic staging for endometrial cancer, the adjuvant management of locally advanced endometrial cancer, whole abdominal irradiation in maximally resected advanced endometrial carcinoma, and combination chemotherapy regimens for stage I and II carcinosarcoma after primary surgery and for advanced or recurrent carcinosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):177-85 [17822748.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Qual Life Res. 2007 Feb;16(1):89-100 [17033909.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5010-6 [17075120.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Am J Obstet Gynecol. 2005 Nov;193(5):1645-9 [16260204.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):630-4 [15721404.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):147-53 [11063636.001]
  • (PMID = 19471650.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676480
  • [Keywords] NOTNLM ; Carcinosarcoma / Clinical trial / Endometrial neoplasm
  •  go-up   go-down


2. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • While whole abdominal radiotherapy has a limited role in early-stage uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC), there may be a role for postoperative chemotherapy and volume-directed radiotherapy in both early-stage UPSC and CC.
  • In the setting of optimally debulked advanced-stage disease, a combination of radiation and chemotherapy may be indicated.
  • CONCLUSIONS: UPSC and CC are managed similarly since sufficient data to separate treatment recommendations are lacking.
  • Because both histologies are associated with a high rate of recurrence, adjuvant therapy is recommended even in women with early-stage disease.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Female. Gynecologic Surgical Procedures. Humans. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


3. Goudy G, Stoeckle E, Thomas L, Kind M, Guyon F, Brouste V, Floquet A: [Prognostic impact of tumour volume and lymph node involvement in intermediate stage T1b1 to T2b cancer of the uterine cervix]. Bull Cancer; 2009 Jun;96(6):685-94
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic impact of tumour volume and lymph node involvement in intermediate stage T1b1 to T2b cancer of the uterine cervix].
  • OBJECTIVE: Determine the prognostic significance of tumour volume and pelvic lymph node status in intermediate stage T1b1 to T2b cancers of the uterine cervix.
  • PATIENTS AND METHODS: Multivariate prognostic factor study in 219 patients (pts), median age 48 years, with stage T1b1 > 2 cm to T2b cervical cancers treated in 91% by primary radio- +/- chemotherapy.
  • RESULTS: Significant prognostic variables in univariate analysis were the ASA anaesthetic score, stage T2b, tumour diameter, involvement of the uterine corpus, radiological (N1) and histological (N+) pelvic lymph node involvement and bilateral N+.
  • In multivariate analysis stage T2b (HR = 2.5; p = 0.003), N+ (HR = 3; p = 0.003) and bilateral N+ (HR = 6.1; p < 0.0001) were independent prognostic factors.
  • CONCLUSION: Stage T2b and pelvic lymph node involvement, but not tumour volume, are the major prognostic factors in intermediate stage cervical cancers.
  • Pelvic lymph node involvement should be determined before treatment.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467961.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Kim RY, Omura GA, Alvarez RD: Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary. Oncology (Williston Park); 2002 Dec;16(12):1669-78; discussion 1678-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary.
  • Over the past few decades, we have gained a better understanding of the risk factors associated with the recurrence of endometrial cancer.
  • Adjuvant postoperative radiotherapy in an intermediate-risk group of endometrial cancer patients resulted in improvement in local control, but survival was not improved significantly.
  • Postoperative management of uterine sarcomas remains investigational.
  • The management of ovarian cancer has notably advanced during the 1990s.
  • Platinum- and paclitaxel-based combination chemotherapy set a new standard of care for patients with advanced ovarian cancer.
  • During the late 1990s, a trend emerged favoring the use of carboplatin over cisplatin for first-line management of advanced ovarian cancer because of its more favorable safety profile.
  • Adjuvant therapy for early-stage high-risk ovarian cancer continues to be actively investigated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Clinical Trials as Topic. Female. Humans. Multicenter Studies as Topic. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12520642.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 43
  •  go-up   go-down


5. Torizuka T, Nakamura F, Takekuma M, Kanno T, Ogusu T, Yoshikawa E, Okada H, Maeda M, Ouchi Y: FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun; 2006 Jun;27(6):481-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer.
  • OBJECTIVE: For surgical planning of uterine corpus cancer, prior knowledge of the depth of myometrial invasion is important.
  • Curative tumour resection is possible in superficial invasion (stages IA and IB), while post-surgical chemotherapy or radiation therapy is required in deep invasion (stage IC).
  • We evaluated the value of positron emission tomography with 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG PET) for estimating the myometrial invasion in uterine corpus cancer.
  • METHODS: We studied 22 patients with clinical stage I uterine corpus cancer, who underwent FDG PET prior to surgery.
  • RESULTS: The surgical stage was IA in five, IB in 11 and IC in six patients.
  • Although both PET and MRI provided correct staging in 14 patients, only MRI overestimated the myometrial invasion in four patients with stage IB and showed inconclusive findings in one patient with stage IC.
  • FDG PET may be feasible for predicting the myometrial infiltration of uterine corpus cancer, especially when uterine atrophy makes it difficult at MRI in post-menopausal patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Myometrium / pathology. Myometrium / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Uterine Neoplasms / pathology. Uterine Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710101.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Kamura T, Jeon JD: Lymph node metastasis in a gynecologic malignancy. Yonsei Med J; 2002 Dec;43(6):783-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A radical hysterectomy was performed on patients with stage IA2 to IIB cervical cancer.
  • For these patients, many histopathological parameters have been reported to be prognostic factors of cervical cancer, such as a pelvic lymph node (PLN) metastasis, the histological subtype, the tumor diameter, the depth of the stromal invasion, a lymph-vascular space invasion (LVSI), a parametrial invasion, a corpus invasion and a vaginal invasion.
  • Ovarian cancer is normally treated with cytoreductive surgery followed by chemotherapy.
  • In order to determine the possibility of individualizing a pelvic lymph node (PLN) dissection in patients with endometrial cancer, the relationship between PLN metastasis and the various prognostic factors was investigated.
  • In this paper, various prognostic variables including a lymph node metastasis were analyzed in cervical cancer, endometrial cancer, and ovarian cancer.
  • [MeSH-minor] Endometrial Neoplasms / pathology. Female. Humans. Lymphatic Metastasis. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12497663.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


7. van Rijswijk RE, Vermorken JB: Drug therapy for gynaecological cancer in older women. Drugs Aging; 2000 Jul;17(1):13-32
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug therapy for gynaecological cancer in older women.
  • Differences in biological behaviour, stage of the disease at presentation, and reluctance to undergo aggressive treatment with its associated morbidity are among the factors thought to be responsible for this difference in outcomes.
  • However, investigations also indicate that elderly patients may receive less surgical and chemotherapeutic treatment without obvious clinical rationale.
  • This overview is aimed at providing a guideline of chemotherapy appropriate for patients with epithelial ovarian, uterine (corpus and cervix), and vulvar cancer, aged 70 to 75 years and over.
  • Platinum-based chemotherapy is the cornerstone of drug treatment in patients with ovarian cancer.
  • Patients aged between 70 and 75 years with a good performance status can be treated with cisplatin- or carboplatin-based chemotherapy.
  • For patients with early recurrence there is no standard treatment, but several cytostatic and hormonal agents can be used with palliative intent.
  • In metastatic endometrial cancer, hormonal therapy is the first choice in tumours expressing a progesterone receptor.
  • Poorly differentiated tumours infrequently respond to endocrine therapy.
  • In this situation, and for patients with tumours that have become resistant to hormonal manipulation, platinum-based chemotherapy may be used.
  • The usefulness of chemotherapy in elderly patients with cervical cancer is limited.
  • Although overall chemoradiation seems superior than radiotherapy alone in patients with locally advanced cervical cancer, the feasibility of this approach in elderly patients needs further investigation.
  • Chemoradiation might also be considered in patients with locally advanced vulvar cancer.
  • However, treatment-related morbidity can be considerable and randomised studies are lacking to prove a survival benefit.
  • Our understanding of the tolerance and effectiveness of chemotherapy in elderly patients is still incomplete due to a paucity of trials that specifically focus on this subset of patients.
  • However, there appears no argument to withhold chemotherapy based purely on age.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Endometrial Neoplasms / drug therapy. Female. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Glandular and Epithelial / drug therapy. Ovarian Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy. Vulvar Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):13-7 [8995541.001]
  • [Cites] Semin Oncol. 1995 Feb;22(1 Suppl 1):3-5 [7863350.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2121-5 [7931482.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(3):187-91 [8508872.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):20-6 [9234915.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3056-61 [8955650.001]
  • [Cites] Obstet Gynecol. 1997 Nov;90(5):748-54 [9351758.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):89-93 [8898175.001]
  • [Cites] Biomed Pharmacother. 1988;42(8):531-8 [2975957.001]
  • [Cites] Semin Oncol. 1994 Feb;21(1):107-13 [8310301.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2654-66 [7989941.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):115-8 [2491882.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):11-7 [7804963.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):397-400 [8112651.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] Br J Cancer. 1989 Apr;59(4):650-3 [2713253.001]
  • [Cites] Ann Oncol. 1993 Apr;4(4):289-94 [8518218.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2 Suppl 2):43-54; quiz 55, 58 [8202720.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1957-68 [7691999.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2405-10 [7902426.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):243-8 [1732425.001]
  • [Cites] Acta Oncol. 1993;32(6):657-61 [7505091.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2159-70 [8635016.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1672-6 [2509641.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2123-34 [9610691.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):270-94 [8001001.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2101-12 [8683243.001]
  • [Cites] Semin Oncol. 1994 Feb;21(1 Suppl 1):17-22 [8153653.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1984 Jun;17(4):285-91 [6235140.001]
  • [Cites] Arch Gerontol Geriatr. 1988 Jun;7(2):119-50 [3046534.001]
  • [Cites] Ann Intern Med. 1994 Jan 15;120(2):104-10 [8256968.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1582-7 [9552069.001]
  • [Cites] Lancet. 1997 Jan 11;349(9045):113-7 [8996432.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1079-85 [3894589.001]
  • [Cites] Ann Oncol. 1992 Mar;3(3):217-22 [1586619.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):693-700 [10442192.001]
  • [Cites] Cancer. 1991 Dec 1;68(11 Suppl):2502-10 [1933793.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2546-51 [8823334.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1697-702 [2119878.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):181-5 [9093728.001]
  • [Cites] Gynecol Oncol. 1996 Dec;63(3):312-7 [8946864.001]
  • [Cites] Acta Oncol. 1995;34(6):813-20 [7576750.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2044-52 [8634998.001]
  • [Cites] J Natl Cancer Inst. 1993 Oct 6;85(19):1580-4 [8411231.001]
  • [Cites] Am J Obstet Gynecol. 1992 May;166(5):1482-5 [1595803.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):638-43 [8420688.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):207-11 [2404837.001]
  • [Cites] Scand Audiol. 1988;17(4):241-7 [3232027.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):172-6 [8996139.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1693-7 [6367971.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):49-53 [7688709.001]
  • [Cites] Eur J Cancer. 1997 Nov;33(13):2167-70 [9470802.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):524-9 [8420672.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):60-3 [8270985.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Gynecol Oncol. 1991 Dec;43(3):233-6 [1752493.001]
  • [Cites] Acta Obstet Gynecol Scand. 1984;63(5):441-50 [6238499.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Curr Opin Oncol. 1996 Sep;8(5):408-14 [8914808.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1187-93 [9555758.001]
  • [Cites] J Am Geriatr Soc. 1996 Apr;44(4):472-4 [8636602.001]
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):49-54 [2909449.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):189-95 [8777177.001]
  • [Cites] Cancer Pract. 1996 May-Jun;4(3):130-4 [8826141.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):387-92 [8774643.001]
  • [Cites] Clin Pharmacol Ther. 1997 Mar;61(3):331-9 [9091249.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):109-12 [8244164.001]
  • [Cites] Cancer Treat Rev. 1994 Apr;20(2):191-214 [8156541.001]
  • [Cites] Br J Cancer. 1994 Jan;69(1):191-5 [8286205.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):393-6 [8774644.001]
  • [Cites] Eur J Cancer. 1994;30A(5):697-8 [8080689.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S143-50 [7835799.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):75-8 [7821851.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1283-6 [2920357.001]
  • [Cites] Am J Obstet Gynecol. 1986 Mar;154(3):639-47 [3953714.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1462-8 [2674333.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-140-S1-50 [9045311.001]
  • [Cites] Lancet. 1998 Nov 14;352(9140):1571-6 [9843101.001]
  • [Cites] Cancer Treat Rep. 1986 Aug;70(8):1019-20 [3731147.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):461-6 [9190976.001]
  • [Cites] Gynecol Oncol. 1993 Jan;48(1):38-49 [8423020.001]
  • [Cites] Semin Oncol. 1993 Feb;20(1):43-9 [8475409.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1530-3 [7932808.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):377-83 [8293403.001]
  • [Cites] Gynecol Oncol. 1993 May;49(2):172-6 [8504984.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26 Suppl:S51-4 [2112053.001]
  • [Cites] Eur J Cancer. 1994;30A(7):911-4 [7946581.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Cancer Invest. 1995;13(3):272-5 [7743379.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1472-8 [8608531.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):4-8 [8995539.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Gynecol Oncol. 1987 Jun;27(2):208-13 [3570058.001]
  • [Cites] Cancer Treat Rep. 1984 May;68(5):809-11 [6722836.001]
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):22-6 [8626111.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):569-73 [9261526.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):137-9 [10094894.001]
  • [Cites] Clin Pharmacol Ther. 1986 Feb;39(2):136-44 [3943271.001]
  • [Cites] Ann Oncol. 1996 Sep;7(7):677-85 [8905025.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] Obstet Gynecol. 1997 Oct;90(4 Pt 1):628-31 [9380328.001]
  • [Cites] Am J Clin Oncol. 1996 Aug;19(4):371-4 [8677907.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):517-23 [8420671.001]
  • [Cites] Oncol Rep. 1996 Mar;3(2):277-9 [21594359.001]
  • [Cites] Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15 [8102012.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Apr;65(2):201-7 [8730625.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1748-53 [7916038.001]
  • [Cites] Cancer Clin Trials. 1981 Fall;4(3):313-6 [6169465.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):141-9 [3543234.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1157-68 [3114434.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):629-38 [10360638.001]
  • [Cites] Anticancer Drugs. 1997 Jun;8(5):432-5 [9215604.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):321-7 [8641609.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):193-8 [8996142.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):51-6 [7557615.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):357-61 [8636744.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):108-14 [2642536.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):405-10 [9469322.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1134-40 [9305715.001]
  • [Cites] Gynecol Oncol. 1977 Mar;5(1):52-8 [404216.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2937-42 [9738561.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):702-9 [3701389.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1748-53 [1357110.001]
  • [Cites] Cancer. 1994 Oct 1;74(7 Suppl):2107-17 [8087778.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):165-71 [8996138.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):606-14 [8420683.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):347-58 [3134277.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2183-93 [9196130.001]
  • [Cites] Lancet. 1989 Jan 21;1(8630):117-20 [2563046.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 1:87-92 [10219460.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):573-80 [7752255.001]
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):359-62 [1693584.001]
  • [Cites] Eur J Cancer. 1991;27(11):1367-72 [1835850.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):187-92 [8996141.001]
  • [Cites] Am J Med. 1989 Feb;86(2):151-7 [2913782.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] Semin Oncol. 1989 Feb;16(1):66-75 [2645651.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-78-S15-82 [9346228.001]
  • [Cites] Gynecol Oncol. 1990 Dec;39(3):332-6 [2258080.001]
  • [Cites] Lancet. 1997 Aug 23;350(9077):535-40 [9284774.001]
  • [Cites] Int J Gynecol Cancer. 1995 Jul;5(4):301-305 [11578494.001]
  • [Cites] Int J Gynecol Cancer. 1994 Jan;4(1):52-60 [11578385.001]
  • [Cites] BMJ. 1991 Oct 12;303(6807):884-93 [1834291.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5432-8 [6386150.001]
  • [Cites] Obstet Gynecol. 1990 Apr;75(4):696-700 [2179783.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):304-9 [3806171.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):269-71 [2070324.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):389-93 [1999708.001]
  • [Cites] BMJ. 1999 Apr 24;318(7191):1108-11 [10213718.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):258-61 [9264573.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):166-71 [2298404.001]
  • [Cites] Gynecol Oncol. 1989 Feb;32(2):198-202 [2910782.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1317-22 [9317185.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):1071-88 [2033421.001]
  • [Cites] J Psychosom Res. 1992 Sep;36(6):531-41 [1640391.001]
  • [Cites] Gynecol Oncol. 1991 Sep;42(3):197-201 [1955180.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):395-401 [8625250.001]
  • [Cites] Int J Gynecol Cancer. 1993 May;3(3):129-142 [11578333.001]
  • [Cites] Semin Oncol. 1992 Oct;19(5):521-8 [1411650.001]
  • [Cites] Gynecol Oncol. 1993 Apr;49(1):86-91 [8482566.001]
  • [Cites] Br J Cancer. 1992 Apr;65(4):621-3 [1314071.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):967-74 [11521804.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1552-7 [8622071.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):282-6 [1473738.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1273-83 [9317180.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):809-16 [8344850.001]
  • [Cites] Gynecol Oncol. 1994 Apr;53(1):33-7 [8175019.001]
  • [Cites] Ann Intern Med. 1990 Dec 1;113(11):834-40 [2146911.001]
  • [Cites] Ann Intern Med. 1989 Aug 15;111(4):273-9 [2569287.001]
  • [Cites] Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):96S-104S [9322876.001]
  • (PMID = 10933513.001).
  • [ISSN] 1170-229X
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 203
  •  go-up   go-down


8. Nassar OA, Abdul Moaty SB, Khalil el-SA, El-Taher MM, El Najjar M: Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst; 2010 Jun;22(2):113-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results.
  • PURPOSE: Uterine corpus sarcomas are rare heterogeneous tumors characterized by rapid progression and poor response to treatment.
  • This series investigated treatment options, relapse pattern, survival and prognostic factors.
  • PATIENTS AND METHODS: A total of 59 patients were treated in the National Cancer Institute, Cairo University, (2000-2007).
  • 40.7% had FIGO stage I disease, 30.5% were II, 16.9% were III and 11.9% were IV.
  • Surgery was the primary line of treatment for all cases with total abdominal hysterectomy and bilateral salpingoophorectomy in 88% of cases and 12% had less extensive surgery.
  • Twenty-four (40.7%) patients had surgery alone, 24 (40.7%) had surgery and radiotherapy, 7 (11.9%) had surgery and chemo-irradiation and 4 (6.7%) had surgery and chemotherapy.
  • Stage, adjuvant irradiation, tumor size, myometrial invasion, vascular and cervix invasion were significant factors in univariate analysis; nevertheless, multivariate prognostic factors were only stage (p=0.04) and adjuvant irradiation (p=0.01).
  • 5-year cumulative disease free survival for stage I was 63.6%, 41.2% for stage II, 10% for stage III and 0% in stage IV.
  • Neither extent of surgery, chemotherapy, histologic type or grade had significant effect on survival.
  • Adjuvant radiotherapy offered 62% 2-year cumulative overall survival versus 22% for surgery alone and surgery with chemotherapy.
  • CONCLUSION: Diagnosis of uterine sarcoma is in itself a poor prognostic factor.
  • KEY WORDS: Uterine cancer - Uterine sarcoma - Uterine sarcoma treatment - Sarcoma irradiation - Sarcoma prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21860468.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


9. Shah JP, Jelsema J, Bryant CS, Ali-Fehmi R, Malone JM Jr: Carboplatin and paclitaxel adjuvant chemotherapy in primitive neuroectodermal tumor of the uterine corpus. Am J Obstet Gynecol; 2009 Feb;200(2):e6-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin and paclitaxel adjuvant chemotherapy in primitive neuroectodermal tumor of the uterine corpus.
  • Primitive neuroectodermal tumor of the uterine corpus (PNET) is rare and appears to have an aggressive clinical course.
  • We report on a postmenopausal woman with optimal surgically cytoreduced advanced-stage PNET in which adjuvant combination chemotherapy with platinum and taxane agents was unsuccessful in extending her disease-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neuroectodermal Tumors, Primitive / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Postmenopause. Radiotherapy, Adjuvant. Uterine Hemorrhage / etiology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110219.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 25
  •  go-up   go-down


10. Mariani A, Webb MJ, Keeney GL, Haddock MG, Aletti G, Podratz KC: Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol; 2002 Oct;87(1):112-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIIC endometrioid corpus cancer includes distinct subgroups.
  • OBJECTIVE: Because stage IIIC corpus cancer is a heterogeneous substage, the outcomes of patients with stage IIIC disease were assessed according to the extent of extrauterine disease.
  • METHODS: From 1984 through 1993, 51 patients with surgical stage IIIC corpus cancer were treated at our institution; 5 patients had tumors with nonendometrioid histologic features and were excluded from the analyses.
  • Of the 46 patients with endometrioid carcinoma, 22 had lymph nodes as the only site of extrauterine disease (stage IIIC(0)) and 24 also had peritoneal cytologic, uterine serosal, adnexal, or vaginal involvement or a combination of these (stage IIIC(ab)).
  • RESULTS: Patients with stage IIIC(0) cancer had a 5-year cause-specific survival (CSS) of 72% and a 5-year recurrence-free survival (RFS) of 68%, and those with stage IIIC(ab) had a CSS of 33% and an RFS of 25% (P < 0.01).
  • Of the 22 patients with stage IIIC(0) endometrioid cancer, 21 had adjuvant radiotherapy (1 also received chemotherapy) and 1 was not treated.
  • Of the 24 patients with stage IIIC(ab) cancer, 16 received adjuvant radiotherapy (1 had concomitant chemotherapy), 2 had chemotherapy, 4 had hormonal therapy, and 2 were not treated.
  • CONCLUSION: Assessment of CSS, RFS, and sites of relapse suggests that FIGO surgical stage IIIC endometrioid corpus cancer includes two distinct and readily separable subgroups:.
  • (1) stage IIIC(0), nodal involvement only, and (2) stage IIIC(ab), nodal plus cytologic, uterine serosal, adnexal, or vaginal involvement, or a combination of these.
  • Our results also suggest that different treatment strategies are needed for these subgroups.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468351.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Johann S, Mueller MD: [Follow-up after malignant tumours of the uterus (cancer of the uterine corpus / cervical cancer)]. Ther Umsch; 2008 Jun;65(6):341-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follow-up after malignant tumours of the uterus (cancer of the uterine corpus / cervical cancer)].
  • Malignant uterine tumours can affect the corpus or the cervix.
  • The endometrial carcinoma with its different histological subtypes counts for most of the malignomas of the uterine body.
  • But the rare category of uterine sarcomas (carcinosarcomas, leiomyosarcomas as well as endometrial stromal sarcomas) also belongs to this group.
  • Cervical cancer presents an own entitity, regarding both histology and therapeutic options.
  • Endometrial cancer is the most common genital malignoma in Northern Europe and North America.
  • Histologically, the endometrial cancer can be subdivided in two groups: type I is hormonal sensitive and well differentiated, type II represents an undifferenciated aggressive tumour with poor prognosis.
  • Due to the main symptom - abnormal vaginal bleeding - endometrial cancer is detected in an early stage in about 75% of all patients.
  • First choice in therapy is stage related surgery.
  • Cervical cancer is mainly a squamous cell carcinoma and oncogenic Human Papilloma Virus (HPV) associated.
  • Surgery is only indicated up to stage IIA, advanced stages should be treated by radio-chemotherapy.
  • Intention is the detection of the curable local relapse.
  • [MeSH-major] Aftercare / methods. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary / diagnosis. Postoperative Complications / diagnosis. Uterine Cervical Neoplasms / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Evidence-Based Medicine. Female. Humans. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Tomography, X-Ray Computed


12. Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE, Comprehensive Cancer Centers TAMARISK-group: Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat; 2008 Nov;112(1):99-108
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
  • Tamoxifen increases the risk of uterine corpus cancer.
  • Since only few, mostly small, studies have examined prognosis of uterine corpus cancer following tamoxifen, we conducted a large retrospective cohort study to further investigate this.
  • We examined histopathologic and immunohistochemical characteristics of 332 patients with uterine corpus cancer following breast cancer, according to tamoxifen use.
  • An increased proportion of FIGO stage III and IV tumors was also observed (20.0% vs. 11.3%, P=0.049).
  • Within FIGO stage I, both short-term and long-term tamoxifen users showed a higher proportion of tumors limited to the endometrium than non-users (35.7% vs. 22.9%, P=0.049 and 0.004 respectively).
  • Uterine corpus cancers in long-term tamoxifen users were more often steroid receptor-negative (ERalpha, PRA and PRB, P<0.05) and P53-positive (P=0.015).
  • Three-year uterine corpus cancer-specific survival was worse for long-term tamoxifen users than for non-users (82% vs. 93% P=0.0001).
  • Our results can be applied when weighing risks and benefits of tamoxifen versus other hormonal agents used in the prevention and treatment of breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Tamoxifen / therapeutic use. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064567.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Investigator] Visser O; Damhuis RA; Louwman WJ; van Dijck JA; Westerman Y; Dirx MJ; Jansen-Landheer ML; de Munck L; Siesling S
  •  go-up   go-down


13. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC: Hematogenous dissemination in corpus cancer. Gynecol Oncol; 2001 Feb;80(2):233-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematogenous dissemination in corpus cancer.
  • OBJECTIVE: The aim of this study was to assess the predictors of hematogenous dissemination (HD) in corpus cancer.
  • METHODS: In 612 corpus cancer patients managed surgically, we defined HD as tumor spread to the lung, liver, or other sites via hematogenous routes.
  • Stage IV disease, positive adnexae, deep myometrial invasion, primary tumor diameter, tumor involving the whole uterine cavity, positive peritoneal cytology, adjuvant radiotherapy, adjuvant chemotherapy, grade 3 histology, histologic subtype, and lymph-vascular invasion significantly (P < or = 0.01) correlated with HD.
  • Considering separately recurrence in the lung and in the liver and recurrence in other sites, the only independent predictors of lung recurrence were stage IV disease and myometrial invasion, whereas independent predictors of HD to the liver/other sites were age and histologic grade.
  • CONCLUSIONS: The presence of deep myometrial invasion was the strongest predictor of HD in corpus cancer, and, together with stage IV disease, it independently predicted lung recurrence.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11161865.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA15083
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


14. King LP, Miller DS: Recent progress: gynecologic oncology group trials in uterine corpus tumors. Rev Recent Clin Trials; 2009 May;4(2):70-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent progress: gynecologic oncology group trials in uterine corpus tumors.
  • The Gynecologic Oncology Group (GOG) has conducted multiple trials related to neoplasms of the uterine corpus.
  • Areas of focus included the feasibility of laparoscopic staging for endometrial cancer, the adjuvant management of locally advanced endometrial cancer, whole abdominal irradiation in maximally resected advanced endometrial carcinoma, and combination chemotherapy regimens for stage I and II carcinosarcoma after primary surgery and for advanced or recurrent carcinosarcoma.
  • [MeSH-major] Clinical Trials as Topic. Uterine Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463102.001).
  • [ISSN] 1876-1038
  • [Journal-full-title] Reviews on recent clinical trials
  • [ISO-abbreviation] Rev Recent Clin Trials
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Number-of-references] 16
  •  go-up   go-down


15. Kaneyasu Y, Okawa T, Yajima M, Saito R, Nakabayashi M, Seshimo A, Kameoka S, Aomi S, Nishikawa T, Sawada T, Mitsuhashi N: Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery. Int J Clin Oncol; 2003 Feb;8(1):60-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery.
  • A case of stage IVB adenoacanthoma of the uterine corpus is described.
  • Computed tomography and magnetic resonance imaging revealed a large tumor accompanied by lymph node involvement in the left inguinal, multiple pelvic, and paraaortic regions.
  • She was diagnosed as having stage IVB endometrial adenoacanthoma.
  • Neoadjuvant chemotherapy with carboplatin (CBDCA) and 5-fluorouracil (5-FU) was performed, followed by radiotherapy.
  • The tumor responded very well, but still remained in Douglas' pouch after treatment.
  • Histopathologically, viable cancer cells were observed only in the fundus of the uterus.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Salvage Therapy. Uterine Neoplasms / therapy. Uterus / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Magnetic Resonance Imaging. Metaplasia / diagnosis. Metaplasia / therapy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12601546.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Trimble EL, Harlan LC, Clegg LX, Stevens JL: Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States. Gynecol Oncol; 2005 Mar;96(3):741-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States.
  • INTRODUCTION: Non-Hispanic black women are less often diagnosed with endometrial cancer than are non-Hispanic white women, but are more likely to die of their disease.
  • METHODS: The Surveillance, Epidemiology, and End-Results Program data were used to sample women newly diagnosed in 1998 with cancer of the corpus uteri.
  • A total of 711 women with no previous diagnosis of cancer were selected.
  • We then sought to verify the therapy provided each woman with her treating physician.
  • RESULTS: Non-Hispanic black women were diagnosed with higher stage, grade, poor histologic subtype, and greater extension of the tumor than were non-Hispanic white women.
  • The use of radiation and chemotherapy increased with stage.
  • CONCLUSIONS: Our study did not show any difference in recommended therapy for women with uterine adenocarcinoma among NH black women, NH white women, and Hispanic women.
  • We must look for other factors, therefore, to explain the disparities in cancer outcome observed among NH black women with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy
  • [MeSH-minor] Adult. African Continental Ancestry Group. Aged. Chemotherapy, Adjuvant. European Continental Ancestry Group. Female. Hispanic Americans. Humans. Middle Aged. Neoplasm Staging. Preoperative Care. Radiotherapy, Adjuvant. SEER Program

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721420.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Wang LH, Xiong Y, Li YF, Li JD, Feng YL, Li YJ, Chen C, Chen L: [Clinical analysis of 12 cases of uterine carcinosarcoma]. Ai Zheng; 2008 May;27(5):516-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 12 cases of uterine carcinosarcoma].
  • BACKGROUND & OBJECTIVE: Uterine carcinosarcoma, also known as malignant mixed mullerian tumors, is an uncommon neoplasm that carries a poor prognosis.
  • This study was to analyze the clinical manifestation, diagnosis, treatment and prognosis of this disease.
  • METHODS: Clinical data of 12 uterine carcinosarcoma patients, diagnosed in Cancer Center of Sun Yat-sen University from 1978 to 2004, were analyzed.
  • RESULTS: Of the 12 cases of uterine carcinosarcoma, 2 were in the cervix, 10 in the corpus uteri.
  • Carcinosarcoma in the corpus uteri manifested abnormal vaginal bleeding and postmenstrual bleeding.
  • Eight patients received chemotherapy and 2 received radiotherapy after operation.
  • CONCLUSIONS: Primary surgery is the main treatment for uterine carcinosarcoma.
  • The prognosis of uterine carcinosarcoma is associated with surgicopathologic stage and treatment modalities.
  • [MeSH-major] Carcinosarcoma / surgery. Hysterectomy / methods. Mixed Tumor, Mullerian / surgery. Uterine Cervical Neoplasms / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate


18. Abdulhathi MB, Al-Salam S, Kassis A, Ghazal-Aswad S: Unusual presentation of cervical cancer as advanced ovarian cancer. Arch Gynecol Obstet; 2007 Oct;276(4):387-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of cervical cancer as advanced ovarian cancer.
  • We report a case of cervical adenocarcinoma presenting primarily as advanced ovarian cancer with the primary site totally silent.
  • Initial investigations with abdominal ultrasound and computerized tomography scan suggested right ovarian dermoid cyst.
  • Surprisingly, the histologic features of the specimen obtained at laparotomy were consistent with a moderately differentiated cervical adenocarcinoma with metastases to corpus uterus, ovaries, left fallopian tube, omentum and pleural cavity.
  • The final stage was stage IV cervical cancer.
  • Following this, the patient was referred to medical oncologist for chemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / diagnosis


19. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, Budczies J, Röske A, Dietel M, Denkert C: Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol; 2009 Jul;135(7):933-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
  • PURPOSE: Endometrial adenocarcinoma, due to a frequent activation of PI3 K/AKT has been proposed as a candidate neoplasm for the treatment with mTOR inhibitors.
  • Yet, data on the expression of mTOR cascade components in endometrial cancer are lacking.
  • METHODS: To provide a basis for futher studies with mTOR inhibitors, we used immunohistochemistry to evaluate the expression of activated mTOR pathway components in 57 endometrial cancer surgical specimens in vivo, and investigated in vitro the relation between the activation of AKT/mTOR and the response to rapamycin.
  • RESULTS: p-mTOR expression was associated with nuclear p-4EBP1 expression (P = 0.02), and was more frequent in tumors extending ouside the uterine corpus (P = 0.011).
  • In cultivated PTEN-deficient Ishikawa cells, in addition to an activation of AKT, a phosphorylation of mTOR and 4EBP1 was evident, while PTEN-wild type HEC-1A cells lacked AKT activation but revealed a reduced expression of p-mTOR and p-4EBP1.
  • CONCLUSISONS: Expression of mTOR and 4EBP1 characterize high-grade, high-stage endometrial adenocarcinomas and might be predictive markers of a response to rapamycin.
  • Based on our results, we suggest that the expression of elements of the mTOR pathway in human tumor tissue should be further evaluated as a possible predictive marker in large-scale clinical studies as well as translational research protocols in clinical studies with mTOR inhibitors.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Phosphoproteins / metabolism. Protein Kinases / metabolism. Sirolimus / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis. TOR Serine-Threonine Kinases. Treatment Outcome. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):184-96 [16412571.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):892-5 [11309338.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):564-75 [15627018.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91 [15028555.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):487-94 [16249016.001]
  • [Cites] Int J Gynecol Cancer. 2003 Mar-Apr;13(2):197-203 [12657124.001]
  • [Cites] Prostate. 2006 Aug 1;66(11):1203-12 [16652388.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56 [16436330.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):177-90 [17196749.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7551-5 [17699757.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6436-46 [17041628.001]
  • [Cites] Cell Cycle. 2007 Jan 1;6(1):65-9 [17245113.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):789-95 [12939469.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4795-9 [17699857.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1758-64 [11410517.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):292-9 [16443261.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1801-11 [16983702.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23 ):10669-73 [16322209.001]
  • [Cites] Mol Cell. 2005 Apr 15;18(2):143-5 [15837416.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6779-88 [15501954.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):81-9 [17200342.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19107520.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


20. Nishio S, Koyanagi T, Miyabe K, Kuromatsu H: [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)]. Gan To Kagaku Ryoho; 2010 Apr;37(4):735-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
  • We report two cases of multidrug-resistant endometrial cancer which recurred after the initial therapy and progressed despite further anticancer chemotherapy, but could be successfully treated with medroxyprogesterone acetate (MPA).
  • The first patient with stage IVb moderately-differentiated endometrioid adenocarcinoma of the uterine corpus underwent initial operation and postoperative chemotherapy followed by maintenance chemotherapy.
  • The second patient with stage IIIc poorly-differentiated endometrioid adenocarcinoma of the uterine corpus developed lung metastases 14 months after the initial operation and postoperative chemotherapy.
  • Subsequent chemotherapy yielded a complete response(CR).
  • Two months later, however, a small intestinal metastasis was observed, which was treated by surgical excision and chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Endometrial Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Middle Aged. Neoplasm Staging. Recurrence. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414038.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


21. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ: Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer; 2000 Jun 15;88(12):2782-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus.
  • METHODS: Patients believed to have disease confined to the uterine corpus who underwent primary surgical assessment were identified and data retrospectively reviewed.
  • Five-year survival for patients with disease confined to the corpus (74%) was significantly greater than for those with more advanced disease (24%, P = 0.0013).
  • Of 24 patients with uterine disease only, 11 received no adjuvant therapy, yet 8 (73%) were free of disease at last follow-up.
  • Neither adjuvant radiotherapy nor chemotherapy was identified as an independent prognostic variable for recurrence or survival.
  • CONCLUSIONS: More than half of patients with CS clinically confined to the uterine corpus harbor occult metastases in a pattern similar to that found with endometrial carcinoma.
  • Although the benefit of adjuvant therapy cannot be demonstrated by this study, a number of early stage patients survive without adjuvant therapy.
  • This argues for extending the International Federation of Gynecology and Obstetrics endometrial carcinoma surgical staging system to include CS, and also for conducting prospective trials to examine the benefits of adjuvant therapy for patients with early stage disease.
  • [MeSH-major] Carcinosarcoma / surgery. Neoplasm Recurrence, Local. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10870061.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


22. el Omari-Alaoui H, Kebdani T, Benjaafar N, el Ghazi E, Erriahni H, el Gueddari BK: [Non-Hodgkin's lymphoma of the uterus: apropos of 4 cases and review of the literature]. Cancer Radiother; 2002 Feb;6(1):39-45
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This rarity explains of one part certain difficulties of the histological diagnosis and on the other hand the absence of a therapeutic strategy clearly established.
  • Two patients had a cervical location, the two other had corpus location.
  • For the corpus location, it is study of the uterus after hysterectomy which retained the diagnosis of lymphoma.
  • The type of the lymphoma was low grade in two cases and high grade in the two other cases.
  • The disease was limited to the pelvis for all our patients (stage IE according to Ann-Arbor's classification).
  • The treatment consisted of an association of chemotherapy and radiotherapy in both cases of lymphoma of the cervix and in a radical hysterectomy followed by chemotherapy for the two cases of lymphoma of the corpus.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Uterine Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Biopsy. Cervix Uteri / pathology. Cyclophosphamide. Diagnosis, Differential. Doxorubicin. Female. Follow-Up Studies. Humans. Hysterectomy. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / radiotherapy. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Prednisone. Radiotherapy Dosage. Time Factors. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / therapy. Uterus / pathology. Vincristine

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11899679.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


23. Ishibashi M, Nakayama K, Shamima Y, Katagiri A, Iida K, Nakayama N, Miyazaki K: [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA]. Gan To Kagaku Ryoho; 2008 May;35(5):857-61
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It accounts for 0.5% of all uterine corpus malignant tumors and 10% of all malignant non-epithelial tumors.
  • MPA is one effective hormonal treatment for ESS.
  • We describe two cases in which patients with metastatic low-grade ESS lesions had prolonged survival with MPA therapy.
  • Case 1 was a 50-year-old woman with a low-grade uterine endometrial stromal tumor who had been operated on at another hospital.
  • She had an incomplete response to chemotherapy.
  • We initiated MPA therapy, which resulted in significant improvement in her metastatic lesions.
  • Case 2 was a 58-year-old woman with stage Ic low-grade ESS who presented with abnormal uterine bleeding.
  • Following surgery (TAH+BSO), MPA therapy was initiated and she had no recurrence.
  • Her cancer recurred with pelvic and paraaortic lymph node metastasis.
  • She was treated with chemotherapy, MPA and radiotherapy.
  • Her metastases improved, and the patient has continued to survive on MPA therapy alone.
  • These cases suggest that MPA might be an effective hormonal therapy for patients with low-grade ESS.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487930.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


24. Zanetta G, Gabriele A, Vecchione F, Landoni F, Isimbaldi G: Unusual recurrence of cervical adenosquamous carcinoma after conservative surgery. Gynecol Oncol; 2000 Mar;76(3):409-12
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of less radical procedures for the treatment of early cervical cancers is gaining interest among physicians and young patients.
  • After a polypectomy, a young patient had a diagnosis of stage Ia(2) cervical adenosquamous carcinoma in 1995.
  • She received chemotherapy postoperatively and remains alive without evidence of disease.
  • The recurrence of cervical cancer is traditionally regarded as an issue concerning the cervix, the parametria, or the lymph nodes.
  • When the uterus is preserved we must also consider the possibility of a recurrence involving the corpus.
  • With wider acceptance of limited therapeutic approaches we must be prepared for the detection of previously unknown patterns of recurrence and the follow-up modalities must be consequently adapted.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Conization. Female. Humans. Lymph Node Excision. Neoplasm Invasiveness. Pregnancy. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10684719.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


25. Camatte S, Morice P, Atallah D, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Castaigne D: Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg; 2002 Sep;195(3):332-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Forty-two patients were treated for BOT with a procedure that included lymphadenectomy.
  • Thirty-two patients underwent systematic lymphadenectomy, five because of associated cancer (uterine cervix or corpus) and five because of bulky nodes discovered during the surgical procedure.
  • None of the patients with early-stage disease (without peritoneal disease) had nodal involvement discovered after routine lymphadenectomy.
  • One patient died of a complication of adjuvant therapy (leukemia after chemotherapy).
  • Routine lymphadenectomy should not be performed in patients with early-stage disease.
  • This procedure should be carried out in patients with serous tumor and enlarged lymph nodes.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / therapy. Cystadenoma, Serous / pathology. Cystadenoma, Serous / therapy. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / therapy. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229940.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement